Bivalirudin in Percutaneous Coronary Intervention, is it the Anticoagulant of Choice?

被引:8
作者
Mahmoud, Ahmed [1 ]
Saad, Marwan [2 ]
Elgendy, Akram Y. [1 ]
Abuzaid, Ahmed [3 ]
Elgendy, Islam Y. [1 ]
机构
[1] Univ Florida, Dept Med, Gainesville, FL 32610 USA
[2] Seton Hall Univ, Dept Med, Sch Hlth & Med Sci, Trinitas Reg Med Ctr, Elizabeth, NJ USA
[3] Creighton Univ, Dept Med, Omaha, NE 68178 USA
关键词
Bivalirudin; Percutaneous coronary intervention; Revascularization; ELEVATION MYOCARDIAL-INFARCTION; GLYCOPROTEIN IIB/IIIA INHIBITORS; UNFRACTIONATED HEPARIN; COST-EFFECTIVENESS; CLINICAL-TRIAL; HORIZONS-AMI; ABCIXIMAB; THERAPY; METAANALYSIS; ANGIOPLASTY;
D O I
10.1111/1755-5922.12124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For decades, unfractionated heparin (UFH) has been widely used in catheterization laboratories for anticoagulation for percutaneous coronary intervention (PCI). The direct thrombin inhibitors, bivalirudin, has emerged as an alternative to UFH for PCI procedures, due to its lower bleeding risk. More recently, randomized trials and meta-analyses questioned the efficacy of bivalirudin, and demonstrated that bivalirudin might be associated with a higher incidence of ischemic events and in particular stent thrombosis. In this review, we discuss the pharmacology of bivalirudin along with the clinical evidence comparing bivalirudin versus UFH in patients undergoing PCI for various indications.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 45 条
  • [1] Cost-Effectiveness of Targeting Patients Undergoing Percutaneous Coronary Intervention for Therapy With Bivalirudin Versus Heparin Monotherapy According to Predicted Risk of Bleeding
    Amin, Amit P.
    Marso, Steven P.
    Rao, Sunil V.
    Messenger, John
    Chan, Paul S.
    House, John
    Kennedy, Kevin
    Robertus, Katherine
    Cohen, David J.
    Mahoney, Elizabeth M.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (04): : 358 - U47
  • [2] Amsterdam EA, 2014, J AM COLL CARDIOL, V64, P2713, DOI [10.1016/j.jacc.2014.10.011, 10.1016/j.jacc.2014.09.017, 10.1016/j.jacc.2014.09.016, 10.1161/CIR.0000000000000134]
  • [3] [Anonymous], AM COLL CARD C 15 SA
  • [4] Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors
    Bangalore, Sripal
    Toklu, Bora
    Kotwal, Anupam
    Volodarskiy, Alexander
    Sharma, Sahil
    Kirtane, Ajay J.
    Feit, Frederick
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [5] TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA
    BITTL, JA
    STRONY, J
    BRINKER, JA
    AHMED, WH
    MECKEL, CR
    CHAITMAN, BR
    MARAGANORE, J
    DEUTSCH, E
    ADELMAN, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) : 764 - 769
  • [6] Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
    Bittl, JA
    Chaitman, BR
    Feit, F
    Kimball, W
    Topol, EJ
    [J]. AMERICAN HEART JOURNAL, 2001, 142 (06) : 952 - 959
  • [7] Novel Approaches for Preventing or Limiting Events (Naples) III Trial Randomized Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at Increased Risk of Bleeding Undergoing Transfemoral Elective Coronary Stenting
    Briguori, Carlo
    Visconti, Gabriella
    Focaccio, Amelia
    Donahue, Michael
    Golia, Bruno
    Selvetella, Lucio
    Ricciardelli, Bruno
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (03) : 414 - 423
  • [8] Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials
    Cassese, Salvatore
    Byrne, Robert A.
    Laugwitz, Karl-Ludwig
    Schunkert, Heribert
    Berger, Peter B.
    Kastrati, Adnan
    [J]. EUROINTERVENTION, 2015, 11 (02) : 196 - 203
  • [9] Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials
    Cavender, Matthew A.
    Sabatine, Marc S.
    [J]. LANCET, 2014, 384 (9943) : 599 - 606
  • [10] Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention - Results from the REPLACE-2 trial
    Cohen, DJ
    Lincoff, AM
    Lavelle, TA
    Chen, HL
    Bakhai, A
    Berezin, RH
    Jackman, D
    Sarembock, IJ
    Topol, EJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) : 1792 - 1800